La demande de brevet déposée par BioArctic pour son candidat médicament exidavnemab destiné au traitement des ...

Early CPAP treatment for individuals with OSA may help reduce the onset of Parkinson disease and other neurodegenerative ...

Researchers from Aarhus University and Synuca Therapeutics recently presented a novel drug-like small-molecule inhibitor of sarco/endoplasmic reticulum calcium ATPase (SERCA), SYN-4569, with superior ...

Researchers from AC Immune SA recently presented the discovery of ACI-21018, a novel α-synuclein aggregation inhibitor developed using AC Immune’s proprietary Morphomer platform.

disordered regions that extend from the fibril core—in prion-like pathological transmission in synucleinopathies. Their work is published in Neuron. The researchers first conducted serial ...

In previous studies, researchers have found an association between OSA and various synucleinopathies, however, no studies have confirmed causal links between OSA and PD. To determine whether OSA ...

Rapid Enrollment and Dosing of First Patients in PRECISE-AD Trial Underscores the Unmet Need for Better Treatment Options for Alzheimer’s Disease “2024 was a transformational year for ProMIS ...